A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment
Tóm tắt
Từ khóa
Tài liệu tham khảo
Baird, 1987, A model for follicular selection and ovulation, J Steroid Biochem, 27, 15, 10.1016/0022-4731(87)90289-5
Chappel, 1992, Expression of human gonadotropins by recombinant DNA methods, 179
Olijve, 1996, Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon), Hum Reprod, 2, 371, 10.1093/molehr/2.5.371
Shoham, 1996, Recombinant technique and gonadotropin production, Fertil Steril, 66, 187, 10.1016/S0015-0282(16)58437-4
Nyboe, 1998, A prospective trial comparing Puregon 150IU and Metrodin-HP 225IU as fixed-dose regimen in IVF treatment, Hum Reprod, 13, 185
Hoomans, 1999, A prospective, randomised clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP) in a fixed-dose regimen in women undergoing ovarian stimulation, Hum Reprod, 14, 2442, 10.1093/humrep/14.10.2442
Out, 1995, A prospective, randomised, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon vs, Metrodin) in in-vitro fertilization. Hum Reprod, 10, 2534
Out, 1997, Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins, Fertil Steril, 68, 138, 10.1016/S0015-0282(97)81490-2
Bergh, 1997, Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP), Hum Reprod, 12, 2133, 10.1093/humrep/12.10.2133
Schats, 2000, Ovarian stimulation during assisted reproduction treatment, Hum Reprod, 15, 1691, 10.1093/humrep/15.8.1691
Frydman, 2000, A double-blind, randomised study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection, Hum Reprod, 15, 520, 10.1093/humrep/15.3.520
Whittemore, 1992, Characteristics relating to ovarian cancer risk, Am J Epidemiol, 136, 1184, 10.1093/oxfordjournals.aje.a116427
Rossing, 1994, Ovarian tumours in a cohort of infertile women, N Engl J Med, 331, 771, 10.1056/NEJM199409223311204
Van Hooff, 1993, Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders, Hum Reprod, 8, 369, 10.1093/oxfordjournals.humrep.a138053
Porchet, 1994, Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modeling after repeated subcutaneous administration, Fertil Steril, 61, 687, 10.1016/S0015-0282(16)56646-1
Mannaerts, 1996, Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon), Hum Reprod Update, 2, 153, 10.1093/humupd/2.2.153
Out, 1999, A prospective, randomised, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation, Hum Reprod, 14, 622, 10.1093/humrep/14.3.622
Out, 2000, Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation, Hum Reprod, 15, 29, 10.1093/humrep/15.1.29
Harrison, 2001, A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin- ) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles, Fertil Steril, 75, 23, 10.1016/S0015-0282(00)01643-5
2001, A double-blind trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization, Fertil Steril, 76, 950, 10.1016/S0015-0282(01)02844-8
de Leeuw, 1996, Structure-function relationship of recombinant follicle stimulating hormone (Puregon), Mol Hum Reprod, 2, 361, 10.1093/molehr/2.5.361
Robertson, 1998, Biopotency of new recombinant follicle stimulating hormone preparations, Hum Reprod, 13, 17
Tulppala, 1999, Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization, Hum Reprod, 14, 2709, 10.1093/humrep/14.11.2709
Harlin, 2000, Recombinant follicle stimulating hormone in in-vitro fertilization treatment—clinical experience with follitropin alpha and follitropin beta, Hum Reprod, 15, 239, 10.1093/humrep/15.2.239
Brinsden, 2000, A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating preparations in patients undergoing in vitro fertilization-embryo transfer, Hum Reprod, 73, 114
Veeck, 1991
Navot, 1992, Ovarian hyperstimulation syndrome in novel reproductive technologies, Fertil Steril, 58, 249, 10.1016/S0015-0282(16)55188-7
Hillier, 1981, Control of preovulatory follicular estrogen biosynthesis in the human ovary, J Clin Endocrinol Metab, 52, 847, 10.1210/jcem-52-5-847
McNatty, 1983, Follicular development during the luteal phase of the human menstrual cycle, J Clin Endocrinol Metab, 56, 1022, 10.1210/jcem-56-5-1022
Karande, 1990, High dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients, Fertil Steril, 53, 486, 10.1016/S0015-0282(16)53345-7
Lashen, 1998, Superovulation with a high gonadotropin dose for in vitro fertilization, J Assist Reprod Genet, 15, 438, 10.1007/BF02744938
Richardson, 1987, Follicular depletion during the menopausal transition, J Clin Endocrinol Metab, 65, 1231, 10.1210/jcem-65-6-1231
Faddy, 1992, Accelerated disappearance of ovarian follicles in mid-life, Hum Reprod, 7, 1342, 10.1093/oxfordjournals.humrep.a137570
Faddy, 1996, A model conforming the decline in follicle numbers to the age of menopause in women, Hum Reprod, 11, 1484, 10.1093/oxfordjournals.humrep.a019422
Tomás, 1997, Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro fertilization, Hum Reprod, 12, 220, 10.1093/humrep/12.2.220
Chang, 1998, Use of the antral follicle count to predict the outcome of assisted reproductive technologies, Fertil Steril, 69, 505, 10.1016/S0015-0282(97)00557-8
Out, 2001, A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles, Hum Reprod, 16, 1104, 10.1093/humrep/16.6.1104
Orvieto, 1998, Ovarian hyperstimulation syndrome, J Soc Gynecol Invest, 5, 110, 10.1016/S1071-5576(97)00113-5